It's Showtime for MAKO Surgical

MAKO Surgical (Nasdaq: MAKO  ) is expected to report Q2 earnings on Aug. 1. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MAKO Surgical's revenues will increase 27.3% and EPS will remain in the red.

The average estimate for revenue is $23.7 million. On the bottom line, the average EPS estimate is -$0.22.

Revenue details
Last quarter, MAKO Surgical logged revenue of $19.6 million. GAAP reported sales were 51% higher than the prior-year quarter's $13.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, EPS came in at -$0.28. GAAP EPS were -$0.28 for Q1 versus -$0.27 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 72.1%, 350 basis points better than the prior-year quarter. Operating margin was -59.9%, 2,490 basis points better than the prior-year quarter. Net margin was -59.7%, 2,470 basis points better than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $109.0 million. The average EPS estimate is -$0.79.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,126 members out of 1,167 rating the stock outperform, and 41 members rating it underperform. Among 252 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 238 give MAKO Surgical a green thumbs-up, and 14 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is hold, with an average price target of $42.25.

The healthcare investing landscape is littered with also-rans and a few major winners. Is MAKO Surgical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of MAKO Surgical. Motley Fool newsletter services recommend MAKO Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 31, 2012, at 2:57 AM, Xrat wrote:

    This article, dated July 30th 2012, contains an advertisement for "Discover the Next Rule-Breaking Multibagger" (which is undated.)

    Under the circumstances, perhaps there should be a 'wealth warning' attached as "Discover the Next Rule-Breaking Multibagger" was presumably written prior to MAKO's value falling by around 60%.

  • Report this Comment On July 31, 2012, at 3:29 PM, Moye100 wrote:

    They should label the article ' Continue to destroy your wealth with MAKO'. I personally think the stock is doomed. It just seems to go down and down. Relentless wealth destruction. I dont know how they can taunt this stock anymore.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1964145, ~/Articles/ArticleHandler.aspx, 11/29/2014 2:44:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement